GlassScriptPhysician profile
Alec S Koo
NPI 1740236066
$151,313.24
in general payments reported to CMS, 2019-2025
60 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $27K · 2021: $25K · 2022: $30K · 2023: $12K · 2024: $4,221 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,109 · Travel and Lodging: $245 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,990.00 |
| Food and Beverage | $5,109.14 |
| Travel and Lodging | $245.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51,249.97 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $41,055.53 | 2019-2025 | |
| Janssen Biotech, INC. | $24,837.81 | 2019-2025 | Erleada |
| Myovant Sciences INC. | $15,479.58 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,949.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,845.13 | 2020-2025 | Lynparza, Imfinzi |
| Sn Holdings, LLC | $1,573.27 | 2021-2023 | |
| Dendreon Pharmaceuticals LLC | $991.13 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $902.05 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $592.40 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $405.09 | 2023-2025 | Orgovyx, Gemtesa |
| Sun Pharmaceutical Industries INC. | $343.68 | 2019-2025 | |
| Blue Earth Diagnostics | $287.66 | 2019-2023 | |
| Tolmar, INC. | $224.06 | 2023-2025 | Eligard |
| Progenics Pharmaceuticals, INC. | $214.85 | 2021-2025 | Pylarify |
Show all 57 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,379,273.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.